Comprehensive approach to sarcopenia treatment

Current Clinical Pharmacology

Volumn 9, Issue 2, 2014, Pages 171-180

  Wakabayashi, Hidetaka ^a   Sakuma, Kunihiro ^b  

^a YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^b TOYOHASHI UNIVERSITY OF TECHNOLOGY   (Japan)

Author keywords

Amino acids; Ghrelin; Growth hormone; Non smoking; Rehabilitation; Resistance training; Sarcopenia; Testosterone

Indexed keywords

AMINO ACID; CAPROMORELIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ESTROGEN; ESTROGEN PLUS PROGESTIN; FISH OIL; FOSINOPRIL; GESTAGEN; GHRELIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; GROWTH HORMONE; GROWTH HORMONE SECRETAGOGUE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IBUTAMOREN; ICOSAPENTAENOIC ACID; NIFEDIPINE; PERINDOPRIL; PLACEBO; PRASTERONE; PROTEIN; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; UNCLASSIFIED DRUG; VITAMIN D;

AGING; ARTHRALGIA; BREAST CANCER; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; CEREBROVASCULAR ACCIDENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DRUG EFFECT; DRUG MEGADOSE; EDEMA; END STAGE RENAL DISEASE; ENDOMETRIUM CANCER; FALLING; FATIGUE; FRACTURE; GLUCOSE BLOOD LEVEL; GYNECOMASTIA; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSOMNIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; MUSCLE ATROPHY; MUSCLE MASS; MUSCLE STRENGTH; MUSCLE WEAKNESS; NUTRITION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RESISTANCE TRAINING; REVIEW; SARCOPENIA; SIDE EFFECT; SMOKING CESSATION; UNSPECIFIED SIDE EFFECT; AGE; AGED; ANIMAL; DIET SUPPLEMENTATION; DISEASE COURSE; PATHOLOGY; PROCEDURES; QUALITY OF LIFE; SKELETAL MUSCLE;

AGE FACTORS; AGED; AGING; ANIMALS; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; HUMANS; MUSCLE, SKELETAL; QUALITY OF LIFE; RESISTANCE TRAINING; SARCOPENIA;

EID: 84906252604     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574884708666131111192845     Document Type: Review

References (95)

1. Rosenberg IH. Summary comments: epidemiological and methodological problems in determining nutritional status of older persons. Am J Clin Nutr 1989; 50: 1231-3.
2. Rosenberg IH. Sarcopenia: Origins and clinical relevance. J Nutr 1997; 127: 990S-1S.
3. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010; 39: 412-23.
4. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc 2011; 12: 249-56.
5. Tanimoto Y, Watanabe M, Sun W, et al. Association of sarcopenia with functional decline in community-dwelling elderly subjects in Japan. Geriatr Gerontol Int 2013; 13: 958-63.
6. Landi F, Liperoti R, Russo A, et al. Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study. Clin Nutr 2012; 31: 652-8.
7. Arango-Lopera VE, Arroyo P, Gutiérrez-Robledo LM, Pérez-Zepeda MU, Cesari M. Mortality as an adverse outcome of sarcopenia. J Nutr Health Aging 2013; 17: 259-62.
8. Baumgartner RN, Koehler KM, Gallagher D, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 1998; 147: 755-63.
9. Arango-Lopera VE, Arroyo P, Gutiérrez-Robledo LM, Pérez-Zepeda MU. Prevalence of sarcopenia in Mexico City. Eur Geriatr Med 2012; 3: 157-60.
10. Landi F, Liperoti R, Fusco D, et al. Prevalence and risk factors of sarcopenia among nursing home older residents. J Gerontol A Biol Sci Med Sci 2012; 67: 48-55.
11. Sakuma K, Yamaguchi A. Molecular mechanisms in aging and current strategies to counteract sarcopenia. Curr Aging Sci 2010; 3: 90-101.
12. Sakuma K, Yamaguchi A. Sarcopenia: molecular mechanisms and current therapeutic strategy. In Cell Aging, Nova Science Publishers, Huntington, NY, USA, 2011, pp 93-152.
13. Sakuma K, Yamaguchi A. Novel intriguing strategies attenuating to sarcopenia. J Aging Res 2012; 251217.
14. Wakabayashi H, Sashika H. Association of nutrition status and rehabilitation outcome in the disuse syndrome: A retrospective cohort study. General Med 2011; 12: 69-74.
15. Bhasin S, Calof OM, Storer TW, et al. Drug insight: Testosterone and selective androgen receptor modulators as anabolic therapies for chronic illness and aging. Nat Clin Pract Endocrinol Metab 2006; 2: 146-59.
16. Ottenbacher KJ, Ottenbacher ME, Ottenbacher AJ, Acha AA, Ostir GV. Androgen treatment and muscle strength in elderly men: A meta-analysis. J Am Geriatr Soc 2006; 54: 1666-73.
17. Fernández-Balsells MM, Murad MH, Lane MA, et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95: 2560-75.
18. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-22.
19. Voznesensky M, Walsh S, Dauser D, Brindisi J, Kenny AM. The association between dehydroepiandrosterone and frailty in older men and women. Age Ageing 2009; 38: 401-6.
20. Baker WL, Karan S, Kenny AM. Effect of dehydroepiandrosterone on muscle strength and physical function in older adults: a systematic review. J Am Geriatr Soc 2011; 59: 997-1002.
21. Greising SM, Baltgalvis KA, Lowe DA, Warren GL. Hormone therapy and skeletal muscle strength: a meta-analysis. J Gerontol A Biol Sci Med Sci 2009; 64: 1071-81.
22. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
23. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2012; 7: CD004143.
24. Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev 2012; 10: CD001405.
25. Liu H, Bravata DM, Olkin I, et al. Systematic review: the safety and efficacy of growth hormone in the healthy elderly. Ann Intern Med 2007; 146: 104-15.
26. White HK, Petrie CD, Landschulz W, et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab 2009; 94: 1198-206.
27. Giannoulis MG, Sonksen PH, Umpleby M, et al. The effects of growth hormone and/or testosterone in healthy elderly men: a randomized controlled trial. J Clin Endocrinol Metab 2006; 91: 477-84.
28. Giannoulis MG, Jackson N, Shojaee-Moradie F, et al. The effects of growth hormone and/or testosterone on whole body protein kinetics and skeletal muscle gene expression in healthy elderly men: a randomized controlled trial. J Clin Endocrinol Metab 2008; 93: 3066-74.
29. Sattler FR, Castaneda-Sceppa C, Binder EF, et al. Testosterone and growth hormone improve body composition and muscle performance in older men. J Clin Endocrinol Metab 2009; 94: 1991-2001.
30. Schroeder ET, He J, Yarasheski KE, et al. Value of measuring muscle performance to assess changes in lean mass with testosterone and growth hormone supplementation. Eur J Appl Physiol 2012; 112: 1123-31.
31. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60.
32. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med 2008; 149: 601-11.
33. Akamizu T, Iwakura H, Ariyasu H, et al. Effects of ghrelin treatment on patients undergoing total hip replacement for osteoarthritis: different outcomes from studies in patients with cardiac and pulmonary cachexia. J Am Geriatr Soc 2008; 56: 2363-5.
34. Nagaya N, Moriya J, Yasumura Y, et al. Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure. Circulation 2004; 110: 3674-9.
35. Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest 2005; 128: 1187-93.
36. Miki K, Maekura R, Nagaya N, et al. Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled trial. PLoS ONE 2012; 7: e35708.
37. Wynne K, Giannitsopoulou K, Small CJ, et al. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebocontrolled trial. J Am Soc Nephrol 2005; 16: 2111-8.
38. Ashby DR, Ford HE, Wynne KJ, et al. Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney Int 2009; 76: 199-206.
39. Neary NM, Small CJ, Wren AM, et al. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89: 2832-6.
40. Strasser F, Lutz TA, Maeder MT, et al. Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer 2008; 98: 300-8.
41. Lundholm K, Gunnebo L, Körner U, et al. Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: a randomized double-blind study. Cancer 2010; 116: 2044-52.
42. Yamamoto K, Takiguchi S, Miyata H, et al. Randomized phase II study of clinical effects of ghrelin after esophagectomy with gastric tube reconstruction. Surgery 2010; 148: 31-8.
43. Adachi S, Takiguchi S, Okada K, et al. Effects of ghrelin administration after total gastrectomy: a prospective, randomized, placebo-controlled phase II study. Gastroenterology 2010; 138: 1312-20.
44. Hiura Y, Takiguchi S, Yamamoto K, et al. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer 2012; 118: 4785-94.
45. Al-Said YA, Al-Rached HS, Al-Qahtani HA, Jan MM. Severe proximal myopathy with remarkable recovery after vitamin D treatment. Can J Neurol Sci 2009; 36: 336-9.
46. Fabbriciani G, Pirro M, Leli C, et al. Diffuse muscoskeletal pain and proximal myopathy: do not forget hypovitaminosis D. J Clin Rheumatol 2010; 16: 34-7.
47. Houston DK, Neiberg RH, Tooze JA, et al. Low 25-hydroxyvitamin D predicts the onset of mobility limitation and disability in community-dwelling older adults: The Health ABC Study. J Gerontol A Biol Sci Med Sci 2013; 68: 181-7.
48. Visser M, Deeg DJ, Lips P, Longitudinal Aging Study Amsterdam. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003; 88: 5766-72.
49. Scott D, Blizzard L, Fell J, Ding C, Winzenberg T, Jones G. A prospective study of the associations between 25-hydroxy-vitamin D, sarcopenia progression and physical activity in older adults. Clin Endocrinol (Oxf) 2010; 73: 581-7.
50. Kim MK, Baek KH, Song KH, et al. Vitamin D deficiency is associated with sarcopenia in older Koreans, regardless of obesity: the Fourth Korea National Health and Nutrition Examination Surveys (KNHANES IV) 2009. J Clin Endocrinol Metab 2011; 96: 3250-6.
51. Seo JA, Cho H, Eun CR, et al. Association between visceral obesity and sarcopenia and vitamin D deficiency in older Koreans: the Ansan Geriatric Study. J Am Geriatr Soc 2012; 60: 700-6.
52. Marantes I, Achenbach SJ, Atkinson EJ, Khosla S, Melton LJ 3rd, Amin S. Is vitamin D a determinant of muscle mass and strength? J Bone Miner Res 2011; 26: 2860-71.
53. Annweiler C, Schott AM, Berrut G, Fantino B, Beauchet O. Vitamin D-related changes in physical performance: a systematic review. J Nutr Health Aging 2009; 13: 893-8.
54. Stockton KA, Mengersen K, Paratz JD, Kandiah D, Bennell KL. Effect of vitamin D supplementation on muscle strength: A systematic review and meta-analysis. Osteoporos Int 2011; 22: 859-71.
55. Murad MH, Elamin KB, Abu Elnour NO, et al. Clinical review: The effect of vitamin D on falls: a systematic review and metaanalysis. J Clin Endocrinol Metab 2011; 96: 2997-3006.
56. Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 2012; 9: CD007146.
57. Bischoff-Ferrari HA, Willett WC, Orav EJ, et al. A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012; 367: 40-9.
58. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010; 303: 1815-22.
59. Onder G, Penninx BW, Balkrishnan R, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 2002; 359: 926-30.
60. Di Bari M, van de Poll-Franse LV, Onder G, et al. Antihypertensive medications and differences in muscle mass in older persons: the Health, Aging and Body Composition Study. J Am Geriatr Soc 2004; 52: 961-6.
61. Gray SL, Aragaki AK, Lamonte MJ, et al. Statins, Angiotensinconverting enzyme inhibitors, and physical performance in older women. J Am Geriatr Soc 2012; 60: 2206-14.
62. Sumukadas D, Witham MD, Struthers AD, McMurdo ME. Effect of perindopril on physical function in elderly people with functional impairment: a randomized controlled trial. CMAJ 2007; 177: 867-74.
63. Bunout D, Barrera G, de la Maza MP, Leiva L, Backhouse C, Hirsch S. Effects of enalapril or nifedipine on muscle strength or functional capacity in elderly subjects. A double blind trial. J Renin Angiotensin Aldosterone Syst 2009; 10: 77-84.
64. Cesari M, Pedone C, Incalzi RA, Pahor M. ACE-inhibition and physical function: results from the Trial of Angiotensin-Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study. J Am Med Dir Assoc 2010; 11: 26-32.
65. Robinson SM, Jameson KA, Batelaan SF, et al. Diet and its relationship with grip strength in community-dwelling older men and women: the Hertfordshire cohort study. J Am Geriatr Soc 2008; 56: 84-90.
66. Smith GI, Atherton P, Reeds DN, et al. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. Am J Clin Nutr 2011; 93: 402-12
67. Rodacki CL, Rodacki AL, Pereira G, et al. Fish-oil supplementation enhances the effects of strength training in elderly women. Am J Clin Nutr 2012; 95: 428-36.
68. Murphy RA, Mourtzakis M, Chu QS, Reiman T, Mazurak VC. Skeletal muscle depletion is associated with reduced plasma (n-3) fatty acids in non-small cell lung cancer patients. J Nutr 2010; 140: 1602-6.
69. Dewey A, Baughan C, Dean T, Higgins B, Johnson I. Eicosapentaenoic acid (EPA, an omega-3 fatty acid from fish oils) for the treatment of cancer cachexia. Cochrane Database Syst Rev 2007; 1: CD004597.
70. Ries A, Trottenberg P, Elsner F, et al. A systematic review on the role of fish oil for the treatment of cachexia in advanced cancer: an EPCRC cachexia guidelines project. Palliat Med 2012; 26: 294-304.
71. Miller MD, Yaxley A, Villani A, et al. A trial assessing N-3 as treatment for injury-induced cachexia (ATLANTIC trial): does a moderate dose fish oil intervention improve outcomes in older adults recovering from hip fracture? BMC Geriatr 2010; 10: 76.
72. Miyachi M, Ando D, Oida Y, et al. Treatment indications for sarcopenia: a systematic review of exercise intervention effect. Nihon Ronen Igakkai Zasshi 2011; 48: 51-4. [Article in Japanese]
73. Peterson MD, Rhea MR, Sen A, Gordon PM. Resistance exercise for muscular strength in older adults: a meta-analysis. Ageing Res Rev 2010; 9: 226-37.
74. Liu CJ, Latham NK. Progressive resistance strength training for improving physical function in older adults. Cochrane Database Syst Rev 2009; 3: CD002759.
75. Singh MA, Ding W, Manfredi TJ, et al. Insulin-like growth factor I in skeletal muscle after weight-lifting exercise in frail elders. Am J Physiol 1999; 277: E135-43.
76. Kosek DJ, Kim JS, Petrella JK, Cross JM, Bamman MM. Efficacy of 3 days/wk resistance training on myofiber hypertrophy and myogenic mechanisms in young vs. older adults. J Appl Physiol 2006; 101: 531-44.
77. Houston DK, Nicklas BJ, Ding J, et al. Dietary protein intake is associated with lean mass change in older, community-dwelling adults: the Health, Aging, and Body Composition (Health ABC) Study. Am J Clin Nutr 2008; 87: 150-5.
78. Milne AC, Potter J, Vivanti A, Avenell A. Protein and energy supplementation in elderly people at risk from malnutrition. Cochrane Database Syst Rev 2009; 2: CD003288.
79. Malafarina V, Uriz-Otano F, Iniesta R, Gil-Guerrero L. Effectiveness of nutritional supplementation on muscle mass in treatment of sarcopenia in old age: a systematic review. J Am Med Dir Assoc 2013; 14: 10-7.
80. Kim HK, Suzuki T, Saito K, et al. Effects of exercise and amino acid supplementation on body composition and physical function in community-dwelling elderly Japanese sarcopenic women: a randomized controlled trial. J Am Geriatr Soc 2012; 60: 16-23.
81. Cermak NM, Res PT, de Groot LC, Saris WH, van Loon LJ. Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. Am J Clin Nutr 2012; 96: 1454-64.
82. Szulc P, Duboeuf F, Marchand F, Delmas PD. Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study. Am J Clin Nutr 2004; 80: 496-503.
83. Castillo EM, Goodman-Gruen D, Kritz-Silverstein D, Morton DJ, Wingard DL, Barrett-Connor E. Sarcopenia in elderly men and women: the Rancho Bernardo study. Am J Prev Med 2003; 25: 226-31.
84. Lee JS, Auyeung TW, Kwok T, Lau EM, Leung PC, Woo J. Associated factors and health impact of sarcopenia in older chinese men and women: a cross-sectional study. Gerontology 2007; 53: 404-10.
85. Saito T, Miyatake N, Sakano N, et al. Relationship between cigarette smoking and muscle strength in Japanese men. J Prev Med Public Health 2012; 45: 381-6.
86. Stenholm S, Tiainen K, Rantanen T, et al. Long-term determinants of muscle strength decline: prospective evidence from the 22-year mini-Finland follow-up survey. J Am Geriatr Soc 2012; 60: 77-85.
87. Brass EP, Sietsema KE. Considerations in the development of drugs to treat sarcopenia. J Am Geriatr Soc 2011; 59: 530-5.
88. Jain NB, Al-Adawi S, Dorvlo AS, Burke DT. Association between body mass index and functional independence measure in patients with deconditioning. Am J Phys Med Rehabil 2008; 87: 21-5.
89. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15:2920-6.
90. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 2010; 21: 1594-8.
91. Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early doselimiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS ONE 2011; 7: e37563.
92. Heber D, Ingles S, Ashley JM, Maxwell MH, Lyons RF, Elashoff RM. Clinical detection of sarcopenic obesity by bioelectrical impedance analysis. Am J Clin Nutr 1996; 64: 472S-7S.
93. Prado CM, Wells JC, Smith SR, Stephan BC, Siervo M. Sarcopenic obesity: a critical appraisal of the current evidence. Clin Nutr 2012; 31: 583-601.
94. Weinheimer EM, Sands LP, Campbell WW. A systematic review of the separate and combined effects of energy restriction and exercise on fat-free mass in middle-aged and older adults: implications for sarcopenic obesity. Nutr Rev 2010; 68: 375-88.
95. Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med 2011; 364: 1218-29.